Current thinking on genetics of chronic obstructive pulmonary disease

Current Opinion in Pulmonary Medicine

Volumn 13, Issue 2, 2007, Pages 107-113

  Molfino, Néstor A ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Candidate gene association studies; Chronic obstructive pulmonary disease; Epigenetics; Genetics; Genome wide association studies

Indexed keywords

ALPHA 1 ANTITRYPSIN; GLUCOCORTICOID;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DNA METHYLATION; DNA POLYMORPHISM; EPIGENETICS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC IDENTIFICATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENOME; HEREDITY; HUMAN; PATHOGENESIS; PHENOTYPE; REPRODUCIBILITY; REVIEW;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33846598460     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328013e97d     Document Type: Review

References (28)

1. Schmidt O, Wilms KH, Lingelbach B. The visby lenses. Optom Vis Sci 1999; 76:624-630.
2. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004; 431:931-945.
3. A haplotype map of the human genome. Nature 2005; 437:1299-1320.
4. Kirov G, Nikolov I, Georgieva L, et al. Pooled DNA genotyping on Affymetrix SNP genotyping arrays. BMC Genomics 2006; 7:27.
5. Feil R. Environmental and nutritional effects on the epigenetic regulation of genes. Mutat Res 2006; 600:46-57.
6. Adcock IM, Ford P, Barnes PJ, Ito K. Epigenetics and airways disease. Respir Res 2006; 7:21. This elegant paper describes how epigenetics are as important as genetics in COPD.
7. Molfino NA. Genetics of COPD. Chest 2004; 125:1929-1940.
8. Hersh CP, DeMeo DL, Lange C, et al. Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol 2005; 33:71-78.
9. National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348:2059-2073.
10. Hersh CP, DeMeo DL, Lazarus R, et al. Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173:977-984.
11. Cookson WO. State of the art: genetics and genomics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3:473-475. This paper explains how and why results of candidate gene studies need to be interpreted with caution.
12. Ott J. Association of genetic loci: replication or not, that is the question. Neurology 2004; 63:955-958.
13. Sandford AJ, Chagani TABA, Weir TD, et al. Susceptibility genes for rapid decline of lung function in the Lung Health Study. Am J Respir Crit Care Med 2001; 163:469-473.
14. Smith CAD, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. The Lancet 1997; 350:630-633.
15. Xiao D, Wang C, Du MJ, et al. Relationship between polymorphisms of genes encoding microsomal epoxide hydrolase and glutathione S-transferase P1 and chronic obstructive pulmonary disease. Chin Med J (Engl) 2004; 117:661-667.
16. Park JY, Chen L, Wadhwa N, Tockman MS. Polymorphisms for microsomal epoxide hydrolase and genetic susceptibility to COPD. Int J Mol Med 2005; 15:443-448.
17. Young RP, Hopkins R, Black PN, et al. Functional variants of antioxidant genes in smokers with COPD and in those with normal lung function. Thorax 2006; 61:394-399.
18. Ye Y, Zhong X, Zhang H. A genome-wide tree- and forest-based association analysis of comorbidity of alcoholism and smoking. BMC Genet 2005; 6 (Suppl 1):S135.
19. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 2006; 38:209-213. The authors describe an alternative strategy with increased power for analyzing data in genome-wide association studies.
20. Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science 1999; 286:481-486.
21. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A 2005; 102:10604-10609. This paper offers a possible explanation to the fact that COPD manifests only in some smokers when they age.
22. Segal E, Fondufe-Mittendorf Y, Chen L, et al. A genomic code for nucleosome positioning. Nature 2006; 442:772-778. This paper has relevance in COPD as it shows how genomic sequences can determine the epigenome.
23. Lee KY, Ito K, Hayashi R, et al. NF-kappaB and activator protein 1 response elements and the role of histone modifications in IL-1beta-induced TGF-beta1 gene transcription. J Immunol 2006; 176:603-615. This papers shows evidence on how hyperacetylation can influence the transcription of cytokines.
24. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352:1967-1976. Is it possible that the severe COPD is associated with a decreased HDAC activity?
25. Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med 2006; 203:7-13. The authors show that the apparent resistance to corticosteroids in COPD is associated with decreased HDAC activity.
26. Rodriguez F, de la Roza C, Jardi R, et al. Glutathione S-transferase P1 and lung function in patients with alpha1-antitrypsin deficiency and COPD. Chest 2005; 127:1537-1543.
27. Agaisse H, Burrack LS, Philips JA, et al. Genome-wide RNAi screen for host factors required for intracellular bacterial infection. Science 2005; 309: 1248-1251.
28. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57:847-852.